齐鲁制药有限公司

About 齐鲁制药有限公司

Qilu Pharmaceutical Group is mainly engaged in the research, development, production and sales of preparations and raw materials for tumors, cardiovascular and cerebrovascular diseases, infections, mental system, nervous system and ophthalmological diseases. It has 13 subsidiaries and more than 23,000 employees. In 2019, it achieved sales revenue of 25.1 billion yuan, paid taxes of 2.3 billion yuan, and achieved exports of 615 million US dollars; it ranked 8th in the 2018 China Pharmaceutical Industry Top 100 List. Qilu Pharmaceutical has always adhered to the innovation-driven strategy, established five R&D platforms linked between China and the United States, with more than 2,000 full-time R&D personnel. More than 6% of annual sales revenue is invested in R&D. There are more than 50 innovative drug projects under research. It has made comprehensive arrangements in fields such as precision targeted therapy, immunotherapy, cell therapy, and new drug delivery systems, and continues to seize new heights in international drug research and development.